|
News Briefs Celera Diagnostics to Market Gene-Based HIV TestDecember 12, 2002 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! Celera Diagnostics, an Alameda, Calif., venture supported by Celera Genomics and Applied Biosystems Group, said it received clearance from the U.S. Food and Drug Administration to market a gene-based HIV test. The test is designed to detect mutations in HIV that create resistance to certain drug treatments. Studies have found that up to 78 percent of patients show resistance to drugs used to treat HIV. Genetic testing is common for HIV patients, but Celera Genomics Chief Executive Kathy Ordoñez said Celera Diagnostics' test could help standardize the process. A unit of Abbott Laboratories will distribute the system. Back to other CDC news for December 12, 2002 Washington Post 12.12.02 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
|